Sugi Predict

Sugi Predict / Compounds / SCHEMBL17522185

SCHEMBL17522185

SCHEMBL17522185

C=CC(=O)Nc1ccc(C)cc1NC(C)C

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.50
▸ HPGD P15428 1/20 0.46
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ FGFR1 P11362 2/20 0.42
▸ FGFR4 P22455 2/20 0.42
▸ MAPK3 P27361 10/20 0.41
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GSTO1 P78417 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17522188 0.94 TGM2 (0.50) TGM2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL18256266 0.87 TGM2 (0.59) TGM2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL21166529 0.86 CYP1A2 (0.46) TGM2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL17522184 0.84 TGM2 (0.49) TGM2CYP2C19FGFR4MAPK3ALDH1A1
SCHEMBL17524715 0.83 TGM2 (0.54) TGM2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL23652898 0.81 TGM2 (0.53) TGM2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL17522206 0.81 TGM2 (0.50) TGM2SMN1; SMN2MAPK3GSTO1ALDH1A1
SCHEMBL5078477 0.79 MEN1 (0.61) TGM2HPGDMAPTSMN1; SMN2MEN1
SCHEMBL31162390 0.79 TGM2 (0.58) TGM2CYP1A2CYP2C19MAPTSMN1; SMN2
SCHEMBL21894170 0.79 TGM2 (0.58) TGM2CYP1A2CYP2C19MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10618902-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases CELGENE CAR LLC (BM) 2020-04-14 — — US disclosed
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-07-18 — — US disclosed
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2017-09-21 — — US disclosed
US-9663524-B2 Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors CELGENE CAR LLC (BM) 2017-05-30 — — US disclosed
US-9663524-B2 Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors CELGENE CAR LLC (BM) 2017-05-30 — — US disclosed
US-20160046634-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2016-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC TGM2 2445/4885HPGD 2410/4885CYP1A2 3803/4885
US-20170267685-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC TGM2 2445/4885HPGD 2410/4885CYP1A2 3803/4885
US-10618902-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases PDXK, DCK, DTYMK TGM2 3342/4885HPGD 1363/4885CYP1A2 3207/4885
US-20160046634-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC TGM2 2445/4885HPGD 2410/4885CYP1A2 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback